At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
- A Study of Acupuncture for Young Adults Who Stopped Getting Periods After Chemotherapy
Full Title Acupuncture for Adolescent and Young Adult Cancer Patients: (AcuAYA)
Purpose
Many people who get chemotherapy experience a loss of their period (amenorrhea). They may have menopause-like symptoms such as insomnia, hot flashes, and anxiety. The condition also increases the risk of infertility.
There is no treatment for period loss in people getting chemotherapy for cancer. Researchers are assessing acupuncture to treat amenorrhea caused by chemotherapy in young adults with cancer.
Acupuncture is a medical technique that involves the insertion of very thin needles into specific areas on the body. The goal is to promote health and well-being. Studies have shown that acupuncture may help recover the function of the ovaries and balance sex hormone levels.
If you join this study, you will be randomly assigned to one of these groups:
- The acupuncture group, who will have 12 acupuncture treatments over 12 weeks.
- The control group, who will be put on a waitlist. They will be able to have the same acupuncture treatment as the acupuncture group after a 16-week waiting period.
Who Can Join
To join this study, there are a few conditions. You must:
- Be English-speaking and under age 40.
- Had stage 1, 2, or 3 cancer diagnosed between the ages of 18 and 39.
- Had been having regular periods at the time of your cancer diagnosis.
- Have completed chemotherapy within the past year.
- Have not had a period for at least 3 months after finishing chemotherapy.
Contact
For more information about this study, please contact the Clinical Research Coordinator at [email protected] or 646-449-1074.
Protocol
25-020Phase
Phase II (phase 2)Investigator
Co-Investigators
Xiaotong LiDiseases
Locations
ClinicalTrials.gov ID
NCT06915116ClinicalTrials.gov
-
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
-
In this study, researchers are assessing the safety and effectiveness of giving the drug disitamab vedotin alone and in combination with pembrolizumab immunotherapy in people with inoperable or metastatic urothelial cancers that make too much of the HER2 protein. Disitamab vedotin targets and kills cancer cells with the HER2 protein. Pembrolizumab boosts the power of the immune system to detect and destroy cancer cells.
- Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma
Full Title Pilot Trial of Homebound Stem Cell Transplantation
Purpose
Autologous stem cell transplantation (ASCT) is a treatment in which some of a patient’s stem cells are removed before high-dose chemotherapy, then returned to the patient to help re-establish the patient’s immune system after chemotherapy. Care for a patient after ASCT usually takes place in a hospital. In this study, researchers want to see if it is feasible to care for a patient at home after ASCT for multiple myeloma. Studies at other institutions suggest that providing care at home after ASCT is safe, increases patient satisfaction, and can lower the risk of infection.
Patients in this study will have their stem cells re-infused in an outpatient setting in the hospital and then continue their care at home.
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have multiple myeloma and plan to have ASCT.
- Patients must have adequate caregiver support and a wireless Internet connection at the home where they will be recovering after ASCT.
- This study is for people ages 18 to 80.
For more information about this study and to inquire about eligibility, please contact Dr. Heather Landau at 212-639-8808.
Protocol
15-022Phase
Pilot (small research study)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT02671448ClinicalTrials.gov
-
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
-
This clinical trial explores a novel approach to treating mantle cell lymphoma (MCL). Researchers are integrating targeted agents into standard induction and maintenance chemoimmunotherapy.  The people in this study have MCL that has not yet been treated.
-
Chemotherapy can cause symptoms, such as nausea and fatigue, and some patients have difficulty working during this treatment. The purpose of this study is to learn more about how chemotherapy for breast cancer affects patients' employment.
- A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Full Title Phase II Study of Second-Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Purpose
The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells.
In this study, patients will receive pembrolizumab with three chemotherapy drugs: gemcitabine, vinorelbine, and liposomal doxorubicin. Depending on how well they respond to this treatment, they may also have ASCT. During ASCT, a patient’s own blood-forming stem cells are collected, and he or she is then treated with high doses of chemotherapy. Afterward, the collected stem cells are re-infused back into the patient to re-establish the blood-forming system.
The drugs used in this study are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have recurrent or persistent Hodgkin lymphoma after no more than one prior regimen of therapy.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 10 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Alison Moskowitz at 212-639-4839.
Protocol
18-160Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT03618550ClinicalTrials.gov
-
CAR T-cell therapy is a form of immunotherapy used to treat some adults with lymphoma. The treatment involves utilizing a patient's own T cells and genetically modifying them in the laboratory to recognize a protein on their cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancerous cells throughout the body.
-
Researchers want to learn if canakinumab can prevent cancer from developing in people with clonal cytopenia of undetermined significance (CCUS). In CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells.